286 related articles for article (PubMed ID: 28345451)
1. The impact of advanced proteomics in the search for markers and therapeutic targets of bladder cancer.
Zhang H; Fan Y; Xia L; Gao C; Tong X; Wang H; Sun L; Ji T; Jin M; Gu B; Fan B
Tumour Biol; 2017 Mar; 39(3):1010428317691183. PubMed ID: 28345451
[TBL] [Abstract][Full Text] [Related]
2. Tissue and serum proteomic profiling for diagnostic and prognostic bladder cancer biomarkers.
Schwamborn K; Gaisa NT; Henkel C
Expert Rev Proteomics; 2010 Dec; 7(6):897-906. PubMed ID: 21142890
[TBL] [Abstract][Full Text] [Related]
3. Biomarker discovery in mass spectrometry-based urinary proteomics.
Thomas S; Hao L; Ricke WA; Li L
Proteomics Clin Appl; 2016 Apr; 10(4):358-70. PubMed ID: 26703953
[TBL] [Abstract][Full Text] [Related]
4. Proteometabolomics of bladder cancer: current and future prospects.
Bansal N; Gupta A; Sankhwar SN
Cancer Biomark; 2015; 15(4):339-48. PubMed ID: 25792474
[TBL] [Abstract][Full Text] [Related]
5. Emerging Bladder Cancer Biomarkers and Targets of Therapy.
Netto GJ; Tafe LJ
Urol Clin North Am; 2016 Feb; 43(1):63-76. PubMed ID: 26614029
[TBL] [Abstract][Full Text] [Related]
6. Potential plasma biomarkers of bladder cancer identified by proteomic analysis: A pilot study.
Lemańska-Perek A; Lis-Kuberka J; Lepczyński A; Dratwa-Chałupnik A; Tupikowski K; Kątnik-Prastowska I; Ożgo M
Adv Clin Exp Med; 2019 Mar; 28(3):339-346. PubMed ID: 29963784
[TBL] [Abstract][Full Text] [Related]
7. Comparative Tissue Proteomics of Microdissected Specimens Reveals Novel Candidate Biomarkers of Bladder Cancer.
Chen CL; Chung T; Wu CC; Ng KF; Yu JS; Tsai CH; Chang YS; Liang Y; Tsui KH; Chen YT
Mol Cell Proteomics; 2015 Sep; 14(9):2466-78. PubMed ID: 26081836
[TBL] [Abstract][Full Text] [Related]
8. Dithiothreitol-based protein equalization technology to unravel biomarkers for bladder cancer.
Araújo JE; López-Fernández H; Diniz MS; Baltazar PM; Pinheiro LC; da Silva FC; Carrascal M; Videira P; Santos HM; Capelo JL
Talanta; 2018 Apr; 180():36-46. PubMed ID: 29332824
[TBL] [Abstract][Full Text] [Related]
9. Large-Scale SRM Screen of Urothelial Bladder Cancer Candidate Biomarkers in Urine.
Duriez E; Masselon CD; Mesmin C; Court M; Demeure K; Allory Y; Malats N; Matondo M; Radvanyi F; Garin J; Domon B
J Proteome Res; 2017 Apr; 16(4):1617-1631. PubMed ID: 28287737
[TBL] [Abstract][Full Text] [Related]
10. Oncoproteomics: Trials and tribulations.
Zhou L; Li Q; Wang J; Huang C; Nice EC
Proteomics Clin Appl; 2016 Apr; 10(4):516-31. PubMed ID: 26518147
[TBL] [Abstract][Full Text] [Related]
11. Discovery of potential bladder cancer biomarkers by comparative urine proteomics and analysis.
Lei T; Zhao X; Jin S; Meng Q; Zhou H; Zhang M
Clin Genitourin Cancer; 2013 Mar; 11(1):56-62. PubMed ID: 22982111
[TBL] [Abstract][Full Text] [Related]
12. Genotypic and phenotypic biomarker profiles for individual risk assessment and cancer detection (lessons from bladder cancer risk assessment in symptomatic patients and workers exposed to benzidine).
Hemstreet GP; Wang W
Front Biosci; 2004 Sep; 9():2671-9. PubMed ID: 15358590
[TBL] [Abstract][Full Text] [Related]
13. Proteomic analysis reveals differentially secreted proteins in the urine from patients with clear cell renal cell carcinoma.
Sandim V; Pereira Dde A; Kalume DE; Oliveira-Carvalho AL; Ornellas AA; Soares MR; Alves G; Zingali RB
Urol Oncol; 2016 Jan; 34(1):5.e11-25. PubMed ID: 26420021
[TBL] [Abstract][Full Text] [Related]
14. Mass spectrometry based proteomics profiling as diagnostic tool in oncology: current status and future perspective.
Findeisen P; Neumaier M
Clin Chem Lab Med; 2009; 47(6):666-84. PubMed ID: 19445650
[TBL] [Abstract][Full Text] [Related]
15. SELDI-TOF-MS proteomics of breast cancer.
Clarke CH; Buckley JA; Fung ET
Clin Chem Lab Med; 2005; 43(12):1314-20. PubMed ID: 16309366
[TBL] [Abstract][Full Text] [Related]
16. Identification of urinary Gc-globulin as a novel biomarker for bladder cancer by two-dimensional fluorescent differential gel electrophoresis (2D-DIGE).
Li F; Chen DN; He CW; Zhou Y; Olkkonen VM; He N; Chen W; Wan P; Chen SS; Zhu YT; Lan KJ; Tan WL
J Proteomics; 2012 Dec; 77():225-36. PubMed ID: 22986152
[TBL] [Abstract][Full Text] [Related]
17. Differential proteomic analysis of nuclear matrix in muscle-invasive bladder cancer: potential to improve diagnosis and prognosis.
Barboro P; Rubagotti A; Orecchia P; Spina B; Truini M; Repaci E; Carmignani G; Romagnoli A; Introini C; Boccardo F; Carnemolla B; Balbi C
Cell Oncol; 2008; 30(1):13-26. PubMed ID: 18219107
[TBL] [Abstract][Full Text] [Related]
18. Clinical proteomics: searching for better tumour markers with SELDI-TOF mass spectrometry.
Engwegen JY; Gast MC; Schellens JH; Beijnen JH
Trends Pharmacol Sci; 2006 May; 27(5):251-9. PubMed ID: 16600386
[TBL] [Abstract][Full Text] [Related]
19. Discovery of Apo-A1 as a potential bladder cancer biomarker by urine proteomics and analysis.
Li C; Li H; Zhang T; Li J; Liu L; Chang J
Biochem Biophys Res Commun; 2014 Apr; 446(4):1047-52. PubMed ID: 24661883
[TBL] [Abstract][Full Text] [Related]
20. Noninvasive approaches for detecting and monitoring bladder cancer.
Talukdar S; Emdad L; Das SK; Sarkar D; Fisher PB
Expert Rev Anticancer Ther; 2015 Mar; 15(3):283-94. PubMed ID: 25494295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
